Zacks Investment Research upgraded shares of Aura Biosciences (NASDAQ:AURA – Get Rating) from a hold rating to a buy rating in a report issued on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $19.00 target price on the stock.
According to Zacks, “Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company’s lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass. “
AURA stock opened at $17.01 on Wednesday. Aura Biosciences has a 1 year low of $13.50 and a 1 year high of $26.16. The stock’s fifty day moving average price is $18.40 and its 200-day moving average price is $18.41.
Institutional investors have recently made changes to their positions in the stock. Citigroup Inc. bought a new stake in Aura Biosciences during the fourth quarter valued at about $31,000. New York State Common Retirement Fund bought a new stake in Aura Biosciences during the fourth quarter valued at about $45,000. California State Teachers Retirement System bought a new stake in Aura Biosciences during the fourth quarter valued at about $51,000. Wells Fargo & Company MN bought a new stake in Aura Biosciences during the fourth quarter valued at about $55,000. Finally, Deutsche Bank AG bought a new stake in Aura Biosciences during the fourth quarter valued at about $56,000. 51.69% of the stock is currently owned by institutional investors.
Aura Biosciences Company Profile (Get Rating)
Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
- Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.